Oxford Immunotec Global (OXFD) Raised to Buy at Zacks Investment Research
Oxford Immunotec Global (NASDAQ:OXFD) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Friday. The firm presently has a $14.00 target price on the stock. Zacks Investment Research‘s target price would suggest a potential upside of 7.86% from the company’s current price.
According to Zacks, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. “
Several other equities analysts also recently commented on the stock. ValuEngine upgraded shares of Oxford Immunotec Global from a “strong sell” rating to a “sell” rating in a research note on Wednesday. BidaskClub downgraded shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research note on Saturday, March 3rd. Cowen restated a “buy” rating and issued a $15.00 price target on shares of Oxford Immunotec Global in a research note on Monday, January 22nd. Finally, BTIG Research set a $21.00 price target on shares of Oxford Immunotec Global and gave the stock a “buy” rating in a research note on Monday, December 18th. Two investment analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Oxford Immunotec Global currently has a consensus rating of “Hold” and a consensus price target of $17.80.
Oxford Immunotec Global (NASDAQ:OXFD) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($0.34) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.02. The business had revenue of $25.03 million during the quarter, compared to the consensus estimate of $25.12 million. Oxford Immunotec Global had a negative net margin of 31.90% and a negative return on equity of 42.38%. The company’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.22) earnings per share. sell-side analysts expect that Oxford Immunotec Global will post -0.9 EPS for the current fiscal year.
In related news, Director Richard A. Sandberg sold 3,000 shares of the business’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $12.01, for a total transaction of $36,030.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 8.11% of the company’s stock.
Several hedge funds have recently modified their holdings of OXFD. Voya Investment Management LLC grew its stake in shares of Oxford Immunotec Global by 16.0% during the second quarter. Voya Investment Management LLC now owns 13,345 shares of the company’s stock worth $224,000 after purchasing an additional 1,845 shares in the last quarter. Alliancebernstein L.P. acquired a new position in shares of Oxford Immunotec Global during the second quarter worth $247,000. Jefferies Group LLC acquired a new position in shares of Oxford Immunotec Global during the fourth quarter worth $273,000. The Manufacturers Life Insurance Company grew its stake in shares of Oxford Immunotec Global by 8.8% during the second quarter. The Manufacturers Life Insurance Company now owns 18,631 shares of the company’s stock worth $313,000 after purchasing an additional 1,500 shares in the last quarter. Finally, Elkfork Partners LLC acquired a new position in shares of Oxford Immunotec Global during the fourth quarter worth $358,000. Hedge funds and other institutional investors own 93.31% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2018/03/11/oxford-immunotec-global-oxfd-raised-to-buy-at-zacks-investment-research.html.
About Oxford Immunotec Global
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.